Advertisement

Topics

Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to...

23:22 EDT 20 Aug 2017 | Topix

Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program's first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.

Original Article: Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to...

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...